Travere Therapeutics, Inc. Common Stock (TVTX) is a publicly traded Healthcare sector company. As of May 21, 2026, TVTX trades at $42.86 with a market cap of $3.99B and a P/E ratio of -148.83. TVTX moved +2.91% today. Year to date, TVTX is +14.12%; over the trailing twelve months it is +147.66%. Its 52-week range spans $12.91 to $48.61. Analyst consensus is strong buy with an average price target of $53.42. Rallies surfaces TVTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes TVTX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $42.86 |
| Market Cap | $3.99B |
| P/E Ratio | -148.83 |
| EPS | $-0.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $48.61 |
| 52-Week Low | $12.91 |
| Volume | 5 |
| Avg Volume | 0 |
| Revenue (TTM) | $490.73M |
| Net Income | $-25.55M |
| Gross Margin | 97.89% |
13 analysts cover TVTX: 0 strong buy, 12 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $53.42.